Results from End-of-Phase 2 Meeting with FDA for IMNN-001 Program in Advanced Ovarian Cancer Announced November 26, 2024
European Commission Approves ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer November 19, 2024
Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer Completed November 5, 2024
First Patient Dosed in Ph 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers November 5, 2024
IGCS 2024: Positive Updated RAMP 201 Data for Avutometinib & Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer Presented October 22, 2024
First Patient Dosed in Ph 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients October 15, 2024
Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs October 8, 2024
Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer September 24, 2024
Two Patients Now Exceeding 1 Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial September 22, 2024
Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers September 3, 2024
11.1 Month Increase in OS in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 in OVATION 2 Ph 2 trial Announced August 6, 2024
Database Lock announced for Ph 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer July 1, 2024
Stenoparib Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer in Ph 2 clinical trial July 1, 2024
FDA places partial clinical hold on Ph 1 ZN-c3-001 in solid tumors, Ph 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and Ph 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC) of azenosertib June 25, 2024
Positive Topline Results from Ph 2 PICCOLO Trial of Mirvetuximab Soravtansine (ELAHERE) for High FRα Expressing Platinum-Sensitive Ovarian Cancer Announced June 11, 2024
Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer June 11, 2024
